KINDLER JEFFREY B 4

What Happened
Jeffrey B. Kindler, a director of Praxis Precision Medicines (PRAX), received three equity awards on February 6, 2026: 688 restricted stock units (RSUs), 478 RSUs, and a 224-share derivative award (total = 1,390 units). All grants were reported as acquisitions (Form 4 code A) with an acquisition price of $0.00 (no cash paid). The RSUs will settle in shares of common stock when they vest; the 224-share derivative award vests in monthly installments (see details below).

Key Details

• Transaction date reported: February 6, 2026; Form 4 filing date: February 10, 2026 (Accession 0001689548-26-000017).
• Awards: 688 RSUs (F1), 478 RSUs (F2), 224 derivative/option-like units (F3) — total 1,390. Reported acquisition price: $0.00 for each award.
• Vesting highlights:
  • 688 RSUs: vest in two equal annual installments on the first two anniversaries of January 8, 2026 (F1).
  • 478 RSUs: vest in a single installment on the earlier of June 26, 2026 or the issuer’s 2026 annual meeting (F2).
  • 224 derivative units: vest in equal monthly installments on the 26th of each month, starting Feb 26, 2026, with the final installment on the earlier of June 26, 2026 or the 2026 annual meeting (F3).
• Settlement: RSUs are cashless and may be settled only by delivery of common stock (per footnotes).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• No sale or exercise occurred—these are grants/awards, not open‑market purchases or dispositions.

Context
These awards are director compensation grants and do not involve an immediate cash transaction or sale of shares. The 224-unit derivative award is not an immediate exercise/sale; it simply vests into shares over the stated months. Grants like these are common for board service and are informative about compensation but do not, by themselves, indicate the director buying or selling stock.